Last reviewed · How we verify
Locametz (Gallium (68Ga) gozetotide)
Locametz works by binding to glutamate carboxypeptidase 2, a protein overexpressed in certain types of cancer, allowing for visualization of cancer cells through PET imaging.
Locametz (Gallium (68Ga) gozetotide) is a positron emission tomography (PET) imaging agent developed by the University of California, Los Angeles (UCLA). It targets glutamate carboxypeptidase 2 (GCPII), a protein overexpressed in certain types of cancer. Locametz was approved by the FDA in 2020 for use in PET imaging. The commercial status of Locametz is patented, and it is not yet available as a generic product. As a PET imaging agent, Locametz is used to help diagnose and monitor cancer.
At a glance
| Generic name | Gallium (68Ga) gozetotide |
|---|---|
| Also known as | Locametz, Illuccix |
| Sponsor | Univ Ca Los Angeles |
| Target | Glutamate carboxypeptidase 2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
| First approval | 2020 |
Mechanism of action
Gallium Ga 68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is + emitting radionuclide that allows PET.
Approved indications
- Positron emission tomography
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Dry mouth
- Injection site reactions
- Injection site hematoma
- Injection site warmth
- Chills
Key clinical trials
- Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients (PHASE2,PHASE3)
- Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence (PHASE2,PHASE3)
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (PHASE3)
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (PHASE3)
- Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial (PHASE2)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) (PHASE2)
- A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Locametz CI brief — competitive landscape report
- Locametz updates RSS · CI watch RSS
- Univ Ca Los Angeles portfolio CI